Wednesday, February 08, 2023 8:43:58 AM
Recent EVAX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/03/2024 11:00:24 AM
- Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress • GlobeNewswire Inc. • 12/02/2024 01:00:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 11/18/2024 09:30:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 02:00:31 PM
- Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing • GlobeNewswire Inc. • 11/13/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 12:30:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 12:04:38 PM
- Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 • GlobeNewswire Inc. • 11/12/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2024 02:20:47 PM
- Evaxion announces business update and third quarter 2024 financial results • GlobeNewswire Inc. • 10/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/28/2024 01:10:59 PM
- Evaxion to announce business update and third quarter 2024 financial results on October 31 • GlobeNewswire Inc. • 10/28/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/09/2024 03:00:07 PM
- Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials • GlobeNewswire Inc. • 10/09/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2024 11:00:13 AM
- Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform • GlobeNewswire Inc. • 10/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/03/2024 11:00:19 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/01/2024 08:30:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/26/2024 12:00:05 PM
- Evaxion significantly expands vaccine development collaboration with MSD • GlobeNewswire Inc. • 09/26/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2024 08:30:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 12:30:06 PM
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 11:30:06 AM
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy • AVAI • Dec 4, 2024 8:00 AM
North Bay Resources Commences Fran Gold Winter Ore Shipment to Bishop Gold Mill, California • NBRI • Dec 2, 2024 9:07 AM
VAYK Reached Agreement on Terms to Acquire $1 Million Company for Disruptive Airbnb Strategy • VAYK • Dec 2, 2024 9:00 AM
ILUS Announces Completion of QIND Acquisition by Fusion Fuel (NASDAQ: HTOO) • ILUS • Nov 27, 2024 12:35 PM
Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer • BLO • Nov 26, 2024 8:48 AM
BioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL • BQST • Nov 26, 2024 8:00 AM